• Gossamer Bio held a special shareholder meeting on July 14, 2026.
• Shareholders authorized potential share issuance tied to conversion of up to $72 million of 7.50% Convertible Senior Secured First Lien Notes due 2030 and exercise of 135,789,000 warrants.
• Investors adopted an amended and restated 2019 Incentive Award Plan, increasing the shares reserved for issuance under the plan.
• Shareholders authorized a charter amendment raising authorized common shares to 4,000,000,000 from 700,000,000; the amendment was filed and became effective.
• Investors also backed alternate charter amendments permitting a reverse stock split with a proportionate cut in authorized shares; no execution was confirmed.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gossamer Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001728117-26-000061), on July 15, 2026, and is solely responsible for the information contained therein.